{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:14:43Z","timestamp":1792826083865,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"\n Importance<\/jats:title>\n The effects of COVID-19 pandemic\u2013related disruptions on cancer diagnosis in the US have been widely observed, but their impact on short-term survival has not been assessed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine 1-year cause-specific survival (CSS) rates among patients diagnosed with cancer during 2020 and 2021 using high-quality cancer registry data.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based cohort study of cancer survival between 2015 and 2021 used the Surveillance, Epidemiology, and End Results 21 Registries (SEER-21) database. The population included individuals with an invasive cancer diagnosis and complete follow-up reported to registries included in SEER-21 between January 1, 2015, and December 31, 2021. Data were analyzed from May 13 to May 27, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n COVID-19 pandemic.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was 1-year CSS rates by stage at diagnosis for patients diagnosed with cancer in 2020 and 2021 compared with trends in 1-year CSS rates among patients diagnosed between 2015 and 2019. Additional site-specific analyses were performed on common cancer sites identified as having low survival (5-year relative survival &amp;lt;33%) or high incidence and high survival (incidence &amp;gt;20.0 per 100\u202f000 and 5-year relative survival \u226566%).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 1\u202f008\u202f012 individuals were diagnosed with cancer during the first 2 years of the COVID-19 pandemic, including 473\u202f781 in 2020 (50.1% female; 51.0% diagnosed at \u226565 years; 11.5% Black, 15.8% Hispanic, 64.1% White, and 7.4% other race) and 534\u202f231 in 2021 (50.3% female; 51.9% diagnosed at \u226565 years; 51.9% diagnosed at \u226565 years; 11.7% Black, 16.2% Hispanic, 62.9% White, and 7.9% other race). Compared with prepandemic trends, significant absolute reductions in 1-year CSS rates occurred for early-stage diagnoses in 2020 (\u22120.44 [95% CI, \u22120.54 to \u22120.34] percentage points) and 2021 (\u22120.27 [95% CI, \u22120.37 to \u22120.16] percentage points) and late-stage diagnoses in 2020 (\u22121.34 [95% CI, \u22121.75 to \u22120.93] percentage points) and 2021 (\u22121.20 [95% CI, \u22121.69 to \u22120.71] percentage points). Survival reductions resulted in an estimated 17\u202f390 more cancer-related deaths (13.1%) within 1 year of diagnosis than expected during the first 2 years of the COVID-19 pandemic. Absolute survival reductions greater than 1.00 percentage point occurred in both years for late-stage diagnoses among individuals of other non-Hispanic race and ethnicity (ie, American Indian and Alaska Native, Asian or Pacific Islander, or unknown race) and individuals aged 65 years or older. Significant site-specific survival reductions also existed in both 2020 and 2021, respectively, for early-stage diagnoses of esophageal cancer (\u22123.89 and \u22123.67 percentage points) and colorectal cancer (\u22121.08 and \u22120.78 percentage points) and late-stage diagnoses of prostate cancer (\u22120.64 and \u22120.77 percentage points).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that individuals diagnosed with cancer in 2020 and 2021 experienced worse short-term survival than those diagnosed between 2015 and 2019, suggesting substantial harms associated with cancer care disruptions during the first 2 years of the COVID-19 pandemic.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.6332","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:30:25Z","timestamp":1770309025000},"page":"356","source":"Crossref","is-referenced-by-count":5,"title":["Survival of Patients Diagnosed With Cancer During the COVID-19 Pandemic"],"prefix":"10.1001","volume":"12","author":[{"given":"Todd","family":"Burus","sequence":"first","affiliation":[{"name":"Markey Cancer Center, University of Kentucky, Lexington"},{"name":"Division of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk","family":"Damgacioglu","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina, Charleston"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[{"name":"Markey Cancer Center, University of Kentucky, Lexington"},{"name":"Division of Cancer Biostatistics, College of Medicine, University of Kentucky, Lexington"},{"name":"Kentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Tucker","sequence":"additional","affiliation":[{"name":"Markey Cancer Center, University of Kentucky, Lexington"},{"name":"Department of Epidemiology & Environmental Health, College of Public Health, University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish A.","family":"Deshmukh","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina, Charleston"},{"name":"Hollings Cancer Center, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle A.","family":"Lang Kuhs","sequence":"additional","affiliation":[{"name":"Markey Cancer Center, University of Kentucky, Lexington"},{"name":"Department of Epidemiology & Environmental Health, College of Public Health, University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"coi250087r1","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2023.6969","article-title":"Undiagnosed cancer cases in the US during the first 10 months of the COVID-19 pandemic.","volume":"10","author":"Burus","year":"2024","journal-title":"JAMA Oncol"},{"issue":"9","key":"coi250087r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.32288","article-title":"COVID-19 and rates of cancer diagnosis in the US.","volume":"7","author":"Burus","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"coi250087r3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/cncr.35026","article-title":"Annual Report to the Nation on the Status of Cancer, part 2: Early assessment of the COVID-19 pandemic\u2019s impact on cancer diagnosis.","volume":"130","author":"Negoita","year":"2024","journal-title":"Cancer"},{"issue":"5","key":"coi250087r4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ijc.34758","article-title":"Changes in cancer incidence rates by stage during the COVID-19 pandemic in the US.","volume":"154","author":"Schafer","year":"2024","journal-title":"Int J Cancer"},{"issue":"17","key":"coi250087r5","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.22.01704","article-title":"Impact of the COVID-19 pandemic on cancer screening delays.","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi250087r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15490","article-title":"Changes in cancer screening in the US during the COVID-19 pandemic.","volume":"5","author":"Fedewa","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"coi250087r7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jnci\/djad191","article-title":"Changes in cancer-related mortality during the COVID-19 pandemic in the United States.","volume":"116","author":"Fedeli","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"coi250087r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40148","article-title":"Alterations in cancer treatment during the first year of the COVID-19 pandemic in the US.","volume":"6","author":"Janczewski","year":"2023","journal-title":"JAMA Netw Open"},{"key":"coi250087r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.oor.2024.100682","article-title":"Head and neck cancer treatment delays in 2021: estimating distributional effects by site, surgery, and p16-positivity.","volume":"12","author":"Semprini","year":"2021","journal-title":"OOR"},{"issue":"7","key":"coi250087r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.22009","article-title":"Racial and ethnic disparities in cancer care during the COVID-19 pandemic.","volume":"5","author":"Patel","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"coi250087r17","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/jnci\/djae086","article-title":"A population-based study of COVID-19 mortality risk in US cancer patients.","volume":"116","author":"Mani","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"coi250087r18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41416-024-02931-0","article-title":"The long-lasting impacts of the COVID-19 pandemic on population-based cancer survival: what are the implications for data analysis?","volume":"132","author":"Stannard","year":"2025","journal-title":"Br J Cancer"},{"issue":"9","key":"coi250087r19","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1055-9965.EPI-19-0125","article-title":"Differences in cancer survival with relative versus cause-specific approaches: an update using more accurate life tables.","volume":"28","author":"Forjaz de Lacerda","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"coi250087r20","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1158\/1055-9965.EPI-21-0423","article-title":"Characterizing trends in cancer patients\u2019 survival using the JPSurv software.","volume":"30","author":"Mariotto","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"coi250087r21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/curroncol30010053","article-title":"Impact of COVID-19 on cancer-related care in the United States: an overview.","volume":"30","author":"Jabbal","year":"2023","journal-title":"Curr Oncol"},{"issue":"18","key":"coi250087r22","doi-asserted-by":"publisher","first-page":"18717","DOI":"10.1002\/cam4.6489","article-title":"Cancer treatment delays among cancer patients living with HIV during the COVID-19 pandemic in the United States.","volume":"12","author":"Khouri","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"coi250087r23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1001\/jamaoncol.2023.4513","article-title":"Assessment of changes in cancer treatment during the first year of the COVID-19 pandemic in the US.","volume":"10","author":"Nogueira","year":"2024","journal-title":"JAMA Oncol"},{"issue":"7","key":"coi250087r24","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/jnci\/djaf011","article-title":"Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.","volume":"117","author":"Fan","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"coi250087r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30072","article-title":"Assessment of time-to-treatment initiation and survival in a cohort of patients with common cancers.","volume":"3","author":"Cone","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"coi250087r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55589","article-title":"Breast and lung cancer screening among Medicare enrollees during the COVID-19 pandemic.","volume":"6","author":"Doan","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"coi250087r27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/XCS.0000000000000772","article-title":"Delay and disparity in observed vs predicted incidence rate of screenable cancer during the COVID-19 pandemic.","volume":"237","author":"Romatoski","year":"2023","journal-title":"J Am Coll Surg"},{"issue":"8","key":"coi250087r28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(23)00293-0","article-title":"Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment.","volume":"24","author":"Han","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi250087r30","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.2020204013","article-title":"Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report.","volume":"2","author":"Mazzone","year":"2020","journal-title":"Radiol Imaging Cancer"},{"issue":"4","key":"coi250087r31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.tige.2021.07.003","article-title":"Impact of the COVID-19 pandemic on utilization of EGD and colonoscopy in the United States: an analysis of the GIQuIC Registry.","volume":"23","author":"Calderwood","year":"2021","journal-title":"Tech Innov Gastrointest Endosc"},{"issue":"9","key":"coi250087r33","doi-asserted-by":"publisher","first-page":"e1454","DOI":"10.1016\/S2214-109X(23)00279-6","article-title":"Health system resilience: a critical review and reconceptualisation.","volume":"11","author":"Witter","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"1","key":"coi250087r34","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1186\/s12913-022-08544-8","article-title":"Health systems resilience in practice: a scoping review to identify strategies for building resilience.","volume":"22","author":"Forsgren","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"coi250087r35","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41416-020-0739-4","article-title":"Errors in determination of net survival: cause-specific and relative survival settings.","volume":"122","author":"Bright","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"coi250087r36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12963-017-0142-4","article-title":"Choice of relative or cause-specific approach to cancer survival analysis impacts estimates differentially by cancer type, population, and application: evidence from a Canadian population-based cohort study.","volume":"15","author":"Withrow","year":"2017","journal-title":"Popul Health Metr"},{"issue":"20","key":"coi250087r37","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/jnci\/djq366","article-title":"Improved estimates of cancer-specific survival rates from population-based data.","volume":"102","author":"Howlader","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"coi250087r38","first-page":"177","article-title":"Determining fitness for use of SEER cause-specific cause of death in analyses of cause-specific survival.","volume":"49","author":"Morawski","year":"2022","journal-title":"J Registry Manag"},{"issue":"9","key":"coi250087r39","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1002\/cam4.1706","article-title":"A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations.","volume":"7","author":"Makkar","year":"2018","journal-title":"Cancer Med"},{"key":"coi250087r15","volume-title":"International Classification of Diseases for Oncology: ICD-O","author":"Fritz","year":"2000","edition":"3rd ed"},{"key":"coi250087r11","unstructured":"SEER*Stat database: incidence\u2013SEER research plus limited-field data, 21 registries (excl IL), Nov 2024 sub (2000-2022)\u2013linked to county attributes\u2013total U.S., 1969-2023 counties. Surveillance, Epidemiology, and End Results Program, National Cancer Institute. Accessed May 13, 2025. https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2024\/"},{"key":"coi250087r12","unstructured":"National Cancer Institute. Race and Hispanic ethnicity changes. 2023. Accessed June 11, 2024. https:\/\/seer.cancer.gov\/seerstat\/variables\/seer\/race_ethnicity\/"},{"key":"coi250087r13","unstructured":"U.S. Department of Agriculture, Economic Research Service. Rural-urban continuum codes. 2020. Accessed March 21, 2024. https:\/\/www.ers.usda.gov\/data-products\/rural-urban-continuum-codes"},{"key":"coi250087r14","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: common cancer sites. National Cancer Institute. Accessed December 19, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/common.html"},{"key":"coi250087r16","unstructured":"National Cancer Institute. SEER*Stat software. Updated November 24, 2025. Accessed January 21, 2026. https:\/\/seer.cancer.gov\/seerstat"},{"key":"coi250087r29","unstructured":"AMN Healthcare. 2022 Survey of physician appointment wait times and Medicare and Medicaid acceptance rates. AMN Healthcare\/Merrit Hawkins. 2022. Accessed April 27, 2024. https:\/\/www.amnhealthcare.com\/amn-insights\/physician\/whitepapers\/survey-of-physician-appointment-wait-times\/"},{"key":"coi250087r32","unstructured":"World Health Organization. Building health system resilience to public health challenges. Accessed November 12, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240094321"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2844749\/jamaoncology_burus_2026_oi_250087_1775759223.95487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:00:51Z","timestamp":1776351651000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2844749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.6332","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}